AXIM Biotechnologies, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Catalina Valencia
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6191 Cornerstone Court, East San Diego CA United States of America 92121
- IPO Date
- Sep 2, 2014
- CIK
- 0001514946
- Website
- aximbiotech.com
- Similar Companies
- Business
- AXIM Biotechnologies, Inc. (OTCQB: AXIM) develops and commercializes point-of-care diagnostic tests primarily for ophthalmological conditions such as dry eye disease (DED) and allergic conjunctivitis; its core products include the FDA-cleared TearScan Lactoferrin test for aqueous deficient DED and the TearScan IgE test for ocular total immunoglobulin E allergy, both utilizing rapid lateral flow immunoassays read by a digital assay reader; the company also advances oncological diagnostics like a 10-minute rapid test for cancer biomarkers, custom assay development services through its vertically integrated R&D platform, and earlier tests for SARS-CoV-2 neutralizing antibodies and fentanyl. Founded in 2010 and headquartered in San Diego, California, AXIM operates a 2,000-square-foot facility in the Sorrento Mesa biotechnology hub, serving eye-care physicians, clinics, and research clients primarily in the United States with global commercialization potential via partnerships. Recent developments include filing a Pre-Submission with the FDA in June 2025 seeking CLIA waiver for its Lactoferrin point-of-care test; receiving a California medical device manufacturing license in March 2024; partnering with Auer Precision in December 2023 for scaled production of IgE and Lactoferrin assays; securing a restock order from commercialization partner Verséa Ophthalmics in February 2024 following clinical validation; and announcing an exclusive distribution agreement with VisionPlus Corp. in October 2025 for TearScan Lactoferrin and IgE tests.
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board
AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test